Your browser doesn't support javascript.
loading
Learning Individual Survival Models from PanCancer Whole Transcriptome Data.
Kumar, Neeraj; Skubleny, Daniel; Parkes, Michael; Verma, Ruchika; Davis, Sacha; Kumar, Luke; Aissiou, Amira; Greiner, Russell.
Afiliação
  • Kumar N; Alberta Machine Intelligence Institute, Edmonton, Alberta, Canada.
  • Skubleny D; Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
  • Parkes M; Computing Science Department, University of Alberta, Edmonton, Alberta, Canada.
  • Verma R; Alberta Machine Intelligence Institute, Edmonton, Alberta, Canada.
  • Davis S; Alberta Machine Intelligence Institute, Edmonton, Alberta, Canada.
  • Kumar L; Microsoft, Vancouver, British Columbia, Canada.
  • Aissiou A; Alberta Health Services, Edmonton, Alberta, Canada.
  • Greiner R; Alberta Machine Intelligence Institute, Edmonton, Alberta, Canada.
Clin Cancer Res ; 29(19): 3924-3936, 2023 10 02.
Article em En | MEDLINE | ID: mdl-37463063
PURPOSE: Personalized medicine attempts to predict survival time for each patient, based on their individual tumor molecular profile. We investigate whether our survival learner in combination with a dimension reduction method can produce useful survival estimates for a variety of patients with cancer. EXPERIMENTAL DESIGN: This article provides a method that learns a model for predicting the survival time for individual patients with cancer from the PanCancer Atlas: given the (16,335 dimensional) gene expression profiles from 10,173 patients, each having one of 33 cancers, this method uses unsupervised nonnegative matrix factorization (NMF) to reexpress the gene expression data for each patient in terms of 100 learned NMF factors. It then feeds these 100 factors into the Multi-Task Logistic Regression (MTLR) learner to produce cancer-specific models for each of 20 cancers (with >50 uncensored instances); this produces "individual survival distributions" (ISD), which provide survival probabilities at each future time for each individual patient, which provides a patient's risk score and estimated survival time. RESULTS: Our NMF-MTLR concordance indices outperformed the VAECox benchmark by 14.9% overall. We achieved optimal survival prediction using pan-cancer NMF in combination with cancer-specific MTLR models. We provide biological interpretation of the NMF model and clinical implications of ISDs for prognosis and therapeutic response prediction. CONCLUSIONS: NMF-MTLR provides many benefits over other models: superior model discrimination, superior calibration, meaningful survival time estimates, and accurate probabilistic estimates of survival over time for each individual patient. We advocate for the adoption of these cancer survival models in clinical and research settings.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transcriptoma / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transcriptoma / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá